Expansion of Stem/Progenitor Cells by Inhibition of Enzymatic Reactions Catalyzed by the SIR2 Family of Enzymes
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,187,876 | Expansion of Stem/Progenitor Cells by Inhibition of Enzymatic Reactions Catalyzed by the SIR2 Family of Enzymes In force · Medium confidence | Gamida-Cell Ltd. | In force | Medium confidence | ||
| US 8,986,992 | Expansion Of Stem/Progenitor Cells By Inhibition Of Enzymatic Reactions Catalyzed By The Sir2 Family Of Enzymes Term ended Term ended Feb 17, 2026 · Low confidence | Gamida Cell Ltd. | Term ended | Term ended Feb 17, 2026 | Term ended Feb 17, 2026 | Low confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Gamida Cell Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.